Simvastatin and lovastatin inhibit breast cell invasion induced by H-Ras

Oncology Reports

Volumn 21, Issue 5, 2009, Pages 1317-1322

  Kang, Soouk ^a   Kim, Eun Sook ^a   Moon, Aree ^a  

^a Duksung Women's University   (South Korea)

Author keywords

3 hydroxy 3 methylglutaryl CoA reductase; Breast cell invasion; H Ras; Matrix metalloproteinase 2

Indexed keywords

FARNESYL DIPHOSPHATE; GELATINASE A; GELATINASE B; MEVINOLIN; RAS PROTEIN; SIMVASTATIN;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER INVASION; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOSOLIC FRACTION; DOWN REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; LOVASTATIN; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; RAS PROTEINS; SIGNAL TRANSDUCTION; SIMVASTATIN;

EID: 67649380732     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000357     Document Type: Article

References (27)

1. Clair T, Miller WR and Cho-Chung YS: Prognostic significance of the expression of a ras protein with a molecular weight of 21,000 by human breast cancer. Cancer Res 47: 5290-5293, 1987.
2. Clark GJ and Der CJ: Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat 35: 133-144, 1995.
3. Watson DM, Elton RA, Jack WJ, Dixon JM, Chetty U and Miller WR: The H-ras oncogene product p21 and prognosis in human breast cancer. Breast Cancer Res Treat 17: 161-169, 1991.
4. Franks LM and Teich NM: Cellular and Molecular Biology of Cancer. Oxford University Press, 1997.
5. Moon A, Kim MS, Kim TG, Kim SH, Kim HE, Chen YQ and Kim HR: H-ras, but not N-ras, induces an invasive phenotype in human breast epithelial cells: a role for MMP-2 in the H-ras-induced invasive phenotype. Int J Cancer 85: 176-181, 2000.
6. Kim MS, Lee EJ, Kim HR and Moon A: p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells. Cancer Res 63: 5454-5461, 2003.
7. Casey PJ, Solski PA, Der CJ and Buss JE: p21 ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci USA 86: 8323-8327, 1989.
8. Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, Bishop WR and Pai JK: K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272: 14459-14464, 1997.
9. Liao JK and Laufs U: Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45: 89-118, 2005.
10. Katz MS: Therapy insight: Potential of statins for cancer chemoprevention and therapy. Nat Clin Pract Oncol 2: 82-89, 2005.
11. Matar P, Rozados VR, Roggero EA and Scharovsky OG: Lovastatin inhibits tumor growth and metastasis development of a rat fibrosarcoma. Cancer Biother Radiopharm 13: 387-393, 1998.
12. Pedersen TR, Wilhelmsen L, Faergeman O, Strandberg TE, Thorgeirsson G, Troedsson L, Kristianson J, Berg K, Cook TJ, Haghfelt T, Kjekshus J, Miettinen T, Olsson AG, Pyörälä K and Wedel H: Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol 86: 257-262, 2000.
13. Fromigue O, Hamidouche Z and Marie PJ: Statin-induced inhibition of 3-hydroxy-3-methyl glutaryl coenzyme a reductase sensitizes human osteosarcoma cells to anticancer drugs. J Pharmacol Exp Ther 325: 595-600, 2008.
14. Moyad MA, Merrick GS, Butler WM, Wallner KE, Galbreath RW, Kurko B and Adamovich E: Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 66: 1150-1154, 2005.
15. Collisson EA, Carranza DC, Chen IY and Kolodney MS: Isoprenylation is necessary for the full invasive potential of RhoA overexpression in human melanoma cells. J Invest Dermatol 119: 1172-1176, 2002.
16. Collisson EA, Kleer C, Wu M, De A, Gambhir SS, Merajver SD and Kolodney MS: Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol Cancer Ther 2: 941-948, 2003.
17. Farina HG, Bublik DR, Alonso DF and Gomez DE: Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells. Clin Exp Metastasis 19: 551-559, 2002.
18. Denoyelle C, Vasse M, Korner M, Mishal Z, Ganné F, Vannier JP, Soria J and Soria C: Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22: 1139-1148, 2001.
19. Furberg CD and Pitt B: Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2: 205-207, 2001.
20. Shin I, Kim S, Song H, Kim HR and Moon A: H-Ras-specific activation of Rac-MKK3/6-p38 pathway: its critical role in invasion and migration of breast epithelial cells. J Biol Chem 280: 14675-14683, 2005.
21. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA and Liao JK: Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 95: 8880-8885, 1998.
22. Blauw GJ, Lagaay AM and Westendorp RG: Statins for prevention of stroke. Lancet 352: 144, 1998.
23. Fritz G: HMG-CoA reductase inhibitors (statins) as anticancer drugs (review). Int J Oncol 27: 1401-1409, 2005.
24. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S and Benz CC: Breast cancer growth prevention by statins. Cancer Res 66: 8707-8714, 2006.
25. Tryggvason K, Hoyhtya M and Pyke C: Type IV collagenases in invasive tumors. Breast Cancer Res Treat 24: 209-218, 1993.
26. Stetler-Stevenson WG, Brown PD, Onisto M, Levy AT and Liotta LA: Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J Biol Chem 265: 13933-13938, 1990.
27. Turner NA, O'Regan DJ, Ball SG and Porter KE: Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. FASEB J 19: 804-806, 2005.